Page 27 - Read Online

Bhasin et al. J Transl Genet Genom 2024;8:55-76 https://dx.doi.org/10.20517/jtgg.2023.46 Page 75

small cell lung cancer. Clin Cancer Res 2020;26:5258-68. DOI
120. Chou J, Egusa EA, Wang S, et al. Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate
cancer. Cancer Res 2023;83:301-15. DOI PubMed PMC
121. Lee JK, Bangayan NJ, Chai T, et al. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of
advanced prostate cancer. Proc Natl Acad Sci USA 2018;115:E4473-82. DOI PubMed PMC
122. Cha S, Yazaki P, Brown C, Shively J. Abstract PO083: treatment of CEA-positive solid tumors with anti-CEA chimeric antigen
receptor T-cells in CEA transgenic mice. Cancer Immunol Res 2021;9:PO083. DOI
123. Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer
Res 2016;22:3425-31. DOI PubMed PMC
124. Li D, Xiang S, Shen J, et al. Comprehensive understanding of B7 family in gastric cancer: expression profile, association with
clinicopathological parameters and downstream targets. Int J Biol Sci 2020;16:568-82. DOI PubMed PMC
125. Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci 2020;16:1767-73. DOI
PubMed PMC
126. Lanka SM, Zorko NA, Antonarakis ES, Barata PC. Metastatic castration-resistant prostate cancer, immune checkpoint inhibitors, and
beyond. Curr Oncol 2023;30:4246-56. DOI PubMed PMC
127. Kontos F, Michelakos T, Kurokawa T, et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res
2021;27:1227-35. DOI PubMed PMC
128. Guo C, Figueiredo I, Gurel B, et al. B7-H3 as a therapeutic target in advanced prostate cancer. Eur Urol 2023;83:224-38. DOI
129. Shi X, Day A, Bergom HE, et al. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-
resistant prostate cancer. NPJ Precis Oncol 2022;6:80. DOI PubMed PMC
130. Li S, Zhang M, Wang M, et al. B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer. Cell Death Discov
2023;9:147. DOI PubMed PMC
131. Benzon B, Zhao SG, Haffner MC, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in
prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis 2017;20:28-35. DOI PubMed PMC
132. Shi W, Wang Y, Zhao Y, et al. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53
deficiencies. Sci Transl Med 2023;15:eadf6724. DOI
133. Mendes AA, Lu J, Kaur HB, et al. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor
activation in prostate cancer. Cancer 2022;128:2269-80. DOI
134. Shenderov E, De Marzo AM, Lotan TL, et al. Neoadjuvant enoblituzumab in localized prostate cancer: a single arm, phase 2 trial.
Nat Med 2023;29:888-97. DOI
135. Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015;21:687-92. DOI
PubMed PMC
136. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol 2010;28:4045-51. DOI PubMed PMC
137. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science
2011;331:1565-70. DOI PubMed
138. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene
2008;27:5869-85. DOI PubMed PMC
139. Le Mercier I, Chen W, Lines JL, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res
2014;74:1933-44. DOI PubMed PMC
140. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T regs in the melanoma tumor microenvironment is driven
+
by CD8 T cells. Sci Transl Med 2013;5:200ra116. DOI PubMed PMC
141. Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of
antileukemic efficacy. Blood 2019;134:2149-58. DOI PubMed PMC
142. Liu S, Deng B, Yin Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic
leukemia. Blood Cancer J 2020;10:15. DOI PubMed PMC
143. Viardot A, Locatelli F, Stieglmaier J, Zaman F, Jabbour E. Concepts in immuno-oncology: tackling B cell malignancies with CD19-
directed bispecific T cell engager therapies. Ann Hematol 2020;99:2215-29. DOI PubMed PMC
144. Li H, Er Saw P, Song E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol
Immunol 2020;17:451-61. DOI PubMed PMC
145. Perera MPJ, Thomas PB, Risbridger GP, et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate
cancer. Cancers 2022;14:503. DOI PubMed PMC
146. Braig F, Brandt A, Goebeler M, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by
disrupted CD19 membrane trafficking. Blood 2017;129:100-4. DOI
147. Kamat NV, Yu EY, Lee JK. BiTE-ing into prostate cancer with bispecific T-cell engagers. Clin Cancer Res 2021;27:2675-7. DOI
PubMed PMC
148. Correnti CE, Laszlo GS, de van der Schueren WJ, et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific
antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 2018;32:1239-43. DOI
PubMed PMC
149. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural